XAGE

SEC source: 0000950170-23-069162 · ownership.xml · nonDerivative · entry 3

Sturgeon Patrick A · CIK 0001822507 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 2,042

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069153 · ownership.xml · nonDerivative · entry 2

Frisch Scott M. · CIK 0001997294 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,147

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069156 · ownership.xml · nonDerivative · entry 2

Spenlehauer Gilles · CIK 0001997250 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,147

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069165 · ownership.xml · nonDerivative · entry 2

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,434

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069161 · ownership.xml · nonDerivative · entry 2

Gregory Kathryn · CIK 0001768530 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,434

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069162 · ownership.xml · nonDerivative · entry 2

Sturgeon Patrick A · CIK 0001822507 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,434

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069153 · ownership.xml · nonDerivative · entry 1

Frisch Scott M. · CIK 0001997294 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 870

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069156 · ownership.xml · nonDerivative · entry 1

Spenlehauer Gilles · CIK 0001997250 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 870

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069165 · ownership.xml · nonDerivative · entry 1

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,087

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069161 · ownership.xml · nonDerivative · entry 1

Gregory Kathryn · CIK 0001768530 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,087

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-069162 · ownership.xml · nonDerivative · entry 1

Sturgeon Patrick A · CIK 0001822507 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Carmell Insiders LLC

Disclosed balance after: 1,087

F1 · ownership.nature: The reported shares acquired and beneficially owned by the Reporting Person represent his/her interest in shares purchased by Carmell Insiders, LLC ("LLC"). The sole purpose of the LLC is to enable certain of the Issuer's Board of Directors to acquire shares of the Issuer's common stock in accordance with the Issuer's Insider Trading Policy (i.e., during periods of time when its members are not in possession of material nonpublic information). The five members of the LLC and their respective percentage interest in it are as follows: David Anderson (21.7%), Scott Frisch (17.4%), Kathryn Gregory (21.7%), Gilles Spenlehauer (17.4%), and Patrick Sturgeon (21.7%). The total amount invested in the LLC by these members was $115,000 as of the date of this filing. The LLC is managed by a non-member, and the members disclaim any voting or investment authority over the LLC.

SEC source: 0000950170-23-067903 · ownership.xml · nonDerivative · entry 4

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,179

SEC source: 0000950170-23-067903 · ownership.xml · nonDerivative · entry 3

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,677

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.51 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.

SEC source: 0000950170-23-067903 · ownership.xml · nonDerivative · entry 2

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,077

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.83 to $2.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2

SEC source: 0000950170-23-067122 · ownership.xml · nonDerivative · entry 1

Cassaday Bryan J. · CIK 0002002588 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500

SEC source: 0000950170-23-067903 · ownership.xml · nonDerivative · entry 1

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,063

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.86 to $2.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0000950170-23-066517 · ownership.xml · nonDerivative · entry 3

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,562

F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.91 to $3.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0000950170-23-066517 · ownership.xml · nonDerivative · entry 2

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,462

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.

SEC source: 0000950170-23-066517 · ownership.xml · nonDerivative · entry 1

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,747

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0000950170-23-065682 · ownership.xml · nonDerivative · entry 3

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,562

SEC source: 0000950170-23-065682 · ownership.xml · nonDerivative · entry 2

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,362

F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.30 to $2.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.

SEC source: 0000950170-23-065682 · ownership.xml · nonDerivative · entry 1

Shukla Rajiv · CIK 0001709033 · Director · Chairman and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,612

F1 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 8

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,750

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 7

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,612

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.43 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 7

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,650

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 6

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,512

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 6

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,450

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 5

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,912

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 5

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,250

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.58 to $3.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4.

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 4

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,050

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 3

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,950

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.63 to $3.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3.

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 4

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,412

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 2

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,650

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 3

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,312

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.57 to $3.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2.

SEC source: 0001213900-23-072561 · ownership.xml · nonDerivative · entry 1

Hubbell Randolph W · CIK 0001984207 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 450

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 2

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,212

SEC source: 0001213900-23-072813 · ownership.xml · nonDerivative · entry 1

Shukla Rajiv · CIK 0001709033 · Director · Executive Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,112

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1.

SEC source: 0001213900-23-057997 · ownership.xml · derivative · entry 5

AHAC Sponsor III LLC · CIK 0001842917 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,971

Underlying: Common Stock · 115,971 shares

Expires 2028-07-14

F5 · kind: The warrants were purchased by the Sponsor on July 29, 2021. The warrants will become exercisable 30 days after the closing of the Business Combination.

F5 · price: The warrants were purchased by the Sponsor on July 29, 2021. The warrants will become exercisable 30 days after the closing of the Business Combination.

SEC source: 0001213900-23-057997 · ownership.xml · derivative · entry 4

AHAC Sponsor III LLC · CIK 0001842917 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 3,786,026 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F1 · kind: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F2 · kind: On July 14, 2023, the Issuer consummated its initial business combination pursuant to the Business Combination Agreement, dated January 4, 2023 (the "Business Combination Agreement"), by and among the Issuer, Candy Merger Sub, Inc. ("Merger Sub") and Carmell Regen Med Corporation (formerly known as Carmell Therapeutics Corporation, "Carmell"), whereby Merger Sub merged with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of the Issuer, and the Issuer changed its name to Carmell Therapeutics Corporation (such merger and the transactions contemplated thereby, collectively, the "Business Combination"). In connection with the closing of the Business Combination, each share of Issuer Class B Common Stock automatically converted on a one-for-one basis into one share of Issuer Class A Common Stock.

F1 · derivative.exercise_date: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F2 · derivative.exercise_date: On July 14, 2023, the Issuer consummated its initial business combination pursuant to the Business Combination Agreement, dated January 4, 2023 (the "Business Combination Agreement"), by and among the Issuer, Candy Merger Sub, Inc. ("Merger Sub") and Carmell Regen Med Corporation (formerly known as Carmell Therapeutics Corporation, "Carmell"), whereby Merger Sub merged with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of the Issuer, and the Issuer changed its name to Carmell Therapeutics Corporation (such merger and the transactions contemplated thereby, collectively, the "Business Combination"). In connection with the closing of the Business Combination, each share of Issuer Class B Common Stock automatically converted on a one-for-one basis into one share of Issuer Class A Common Stock.

F1 · derivative.expiration_date: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F2 · derivative.expiration_date: On July 14, 2023, the Issuer consummated its initial business combination pursuant to the Business Combination Agreement, dated January 4, 2023 (the "Business Combination Agreement"), by and among the Issuer, Candy Merger Sub, Inc. ("Merger Sub") and Carmell Regen Med Corporation (formerly known as Carmell Therapeutics Corporation, "Carmell"), whereby Merger Sub merged with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of the Issuer, and the Issuer changed its name to Carmell Therapeutics Corporation (such merger and the transactions contemplated thereby, collectively, the "Business Combination"). In connection with the closing of the Business Combination, each share of Issuer Class B Common Stock automatically converted on a one-for-one basis into one share of Issuer Class A Common Stock.

SEC source: 0001213900-23-057997 · ownership.xml · nonDerivative · entry 3

AHAC Sponsor III LLC · CIK 0001842917 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,249,908

F4 · kind: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of Issuer Class A Common Stock was reclassified on a one-for-one basis into one share of common stock of the Issuer.

F4 · price: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of Issuer Class A Common Stock was reclassified on a one-for-one basis into one share of common stock of the Issuer.

F3 · ownership.direct: AHAC Sponsor III LLC (the "Sponsor") is the record holder of the shares reported herein. Rajiv Shukla, the Issuer's Executive Chairman of the Board of Directors, is the managing member of the Sponsor and may be deemed the beneficial owner of the shares held by the Sponsor. Mr. Shukla disclaims beneficial ownership over any securities in which he does not have a pecuniary interest.

SEC source: 0001213900-23-057997 · ownership.xml · nonDerivative · entry 2

AHAC Sponsor III LLC · CIK 0001842917 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · kind: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of Issuer Class A Common Stock was reclassified on a one-for-one basis into one share of common stock of the Issuer.

F4 · price: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of Issuer Class A Common Stock was reclassified on a one-for-one basis into one share of common stock of the Issuer.

F3 · ownership.direct: AHAC Sponsor III LLC (the "Sponsor") is the record holder of the shares reported herein. Rajiv Shukla, the Issuer's Executive Chairman of the Board of Directors, is the managing member of the Sponsor and may be deemed the beneficial owner of the shares held by the Sponsor. Mr. Shukla disclaims beneficial ownership over any securities in which he does not have a pecuniary interest.

SEC source: 0001213900-23-057997 · ownership.xml · nonDerivative · entry 1

AHAC Sponsor III LLC · CIK 0001842917 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,249,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F2 · kind: On July 14, 2023, the Issuer consummated its initial business combination pursuant to the Business Combination Agreement, dated January 4, 2023 (the "Business Combination Agreement"), by and among the Issuer, Candy Merger Sub, Inc. ("Merger Sub") and Carmell Regen Med Corporation (formerly known as Carmell Therapeutics Corporation, "Carmell"), whereby Merger Sub merged with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of the Issuer, and the Issuer changed its name to Carmell Therapeutics Corporation (such merger and the transactions contemplated thereby, collectively, the "Business Combination"). In connection with the closing of the Business Combination, each share of Issuer Class B Common Stock automatically converted on a one-for-one basis into one share of Issuer Class A Common Stock.

F1 · price: As described in the registration statement of Alpha Healthcare Acquisition Corp. III (the "Issuer") on Form S-1 (File No. 333-253876) under the heading "Description of Securities," the shares of Class B common stock of the Issuer ("Issuer Class B Common Stock") will automatically convert into shares of Class A common stock of the Issuer ("Issuer Class A Common Stock") at the time of the Issuer's initial business combination on a one-for-one basis subject to certain adjustments and have no expiration date.

F2 · price: On July 14, 2023, the Issuer consummated its initial business combination pursuant to the Business Combination Agreement, dated January 4, 2023 (the "Business Combination Agreement"), by and among the Issuer, Candy Merger Sub, Inc. ("Merger Sub") and Carmell Regen Med Corporation (formerly known as Carmell Therapeutics Corporation, "Carmell"), whereby Merger Sub merged with and into Carmell, with Carmell surviving the merger as a wholly-owned subsidiary of the Issuer, and the Issuer changed its name to Carmell Therapeutics Corporation (such merger and the transactions contemplated thereby, collectively, the "Business Combination"). In connection with the closing of the Business Combination, each share of Issuer Class B Common Stock automatically converted on a one-for-one basis into one share of Issuer Class A Common Stock.

F3 · ownership.direct: AHAC Sponsor III LLC (the "Sponsor") is the record holder of the shares reported herein. Rajiv Shukla, the Issuer's Executive Chairman of the Board of Directors, is the managing member of the Sponsor and may be deemed the beneficial owner of the shares held by the Sponsor. Mr. Shukla disclaims beneficial ownership over any securities in which he does not have a pecuniary interest.

SEC source: 0001062993-23-015058 · form4.xml · derivative · entry 4

NEWLIN WILLIAM R · CIK 0001076972 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Newlin Investment 1 LLC

Disclosed balance after: 35,304

Underlying: Common Stock · 35,304 shares

Expires 2032-09-30

F5 · kind: As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F5 · price: As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F4 · derivative.exercise_date: These warrants are currently exercisable.

F1 · ownership.nature: Mr. Newlin is Chairman and Founder of Newlin Investment 1 LLC. By virtue of this relationship, Mr. Newlin may be deemed to share beneficial ownership of the securities held of record by Newlin Investment 1 LLC. Mr. Newlin disclaims any such beneficial ownership except to the extent of his pecuniary interest.

SEC source: 0001062993-23-015058 · form4.xml · derivative · entry 3

NEWLIN WILLIAM R · CIK 0001076972 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Newlin Investment 1 LLC

Disclosed balance after: 482

Underlying: Common Stock · 482 shares

Expires 2024-09-30

F5 · kind: As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F5 · price: As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F4 · derivative.exercise_date: These warrants are currently exercisable.

F1 · ownership.nature: Mr. Newlin is Chairman and Founder of Newlin Investment 1 LLC. By virtue of this relationship, Mr. Newlin may be deemed to share beneficial ownership of the securities held of record by Newlin Investment 1 LLC. Mr. Newlin disclaims any such beneficial ownership except to the extent of his pecuniary interest.

SEC source: 0001062993-23-015058 · form4.xml · derivative · entry 2

NEWLIN WILLIAM R · CIK 0001076972 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,167

Underlying: Common Stock · 108,167 shares

Expires 2031-09-23

F3 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

F2 · derivative.exercise_date: Options to purchase 108,167 shares of common stock of Legacy Carmell (as defined below) granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2021 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.

SEC source: 0001062993-23-015050 · form4.xml · derivative · entry 4

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,173

Underlying: Common Stock · 32,173 shares

Expires 2031-09-23

F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

F3 · derivative.exercise_date: Options to purchase 32,173 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.

SEC source: 0001062993-23-015050 · form4.xml · derivative · entry 3

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,509

Underlying: Common Stock · 8,509 shares

Expires 2029-07-19

F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

F2 · derivative.exercise_date: Options to purchase 8,509 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: (i) 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% will vest on July 19, 2023.

SEC source: 0001062993-23-015050 · form4.xml · derivative · entry 2

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,910

Underlying: Common Stock · 19,910 shares

Expires 2027-06-20

F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

F1 · derivative.exercise_date: Options are fully vested and exercisable.

SEC source: 0001062993-23-015050 · form4.xml · derivative · entry 1

Anderson David W · CIK 0001304554 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,285

Underlying: Common Stock · 16,285 shares

Expires 2026-07-16

F4 · price: On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

F1 · derivative.exercise_date: Options are fully vested and exercisable.

SEC source: 0001062993-23-015056 · form4.xml · derivative · entry 5

Upton Richard A · CIK 0001375726 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Harbor Light Direct Investment, LP

Disclosed balance after: 69

Underlying: Common Stock · 69 shares

Expires 2032-09-30

F5 · kind: As part of the Business Combination, existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F5 · price: As part of the Business Combination, existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

F4 · derivative.exercise_date: These warrants are currently exercisable.

F1 · ownership.nature: Mr. Upton is General Partner at Harbor Light Capital Partners, which is affiliated with the entities listed above. By virtue of this relationship, Mr. Upton may be deemed to share beneficial ownership of the securities held of record by the entities listed above. Mr. Upton disclaims any such beneficial ownership except to the extent of his pecuniary interest.